ArticleBritish journal of cancer2026
STK32C activated IL-6/JAK2/STAT3 signaling and promoted tumor angiogenesis.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAngiogenesis is essential for colorectal cancer (CRC) progression. The role of serine/threonine kinase STK32C in this process remains unclear.
methodsSTK32C expression was examined in CRC tissues and correlated with patient prognosis. In vitro assays evaluated endothelial proliferation, migration, and tube formation. Mechanisms were studied using immunoprecipitation, western blotting, and gene set enrichment analysis. In vivo, xenograft and Matrigel plug assays assessed tumor growth and angiogenesis.
resultsSTK32C was markedly overexpressed in CRC and associated with poor outcomes. Overexpression promoted endothelial angiogenic behaviors, while knockout suppressed them. Mechanistically, STK32C directly phosphorylated STAT3 at Thr196, enhancing its binding to JAK2 and activating IL-6/JAK2/STAT3 signaling. In vivo, STK32C depletion reduced tumor growth, VEGF-A expression, and microvessel density, confirming its pro-angiogenic function. STK32C-mediated tumor angiogenesis relied on STAT3 Thr196 phosphorylation.
conclusionsSTK32C acts as a pro-angiogenic driver in CRC by activating IL-6/JAK2/STAT3 signaling via STAT3 Thr196 phosphorylation. Its strong association with poor prognosis highlights STK32C as a potential biomarker and therapeutic target in anti-angiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.